The Motley Fool··Motley Fool TranscribingAlpha Cognition Posts 40% Sequential Revenue Growth on Alzheimer's Drug Momentum
Alpha Cognition reported Q1 2026 revenue of $3.5M, up 40% sequentially, driven by ZUNVEYL Alzheimer's drug sales and expanded prescriber base.
ACOGrevenue growthQ1 2026 earnings